Sanjay Emandi, MD
Radiation Oncology · Paris, TXNPI 1275532095
Payments from drug & device makers
Across 43 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$150
- Lilly USA, LLC$92
- Merck$87
- AbbVie$77
- Takeda Pharmaceuticals U.S.A., Inc.$57
- AVEO Pharmaceuticals, Inc.$52
- plus $397 from 17 others
What the payments were for
- Food & beverage$88897%
- Education$243%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 6 | $150 |
| Lilly USA, LLC | 5 | $92 |
| Merck | 4 | $87 |
| AbbVie | 3 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $57 |
| AVEO Pharmaceuticals, Inc. | 2 | $52 |
| Sobi, Inc | 2 | $44 |
| Johnson & Johnson | 2 | $36 |
| Rigel Pharmaceuticals, Inc. | 2 | $35 |
| Astellas Pharma US Inc | 2 | $34 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $25 |
| Geron Corporation | 1 | $24 |
| Myovant Sciences Inc. | 1 | $24 |
| Pfizer | 1 | $24 |
| ADC Therapeutics America, Inc. | 1 | $20 |
| Morphosys, US Inc. | 1 | $19 |
| Karyopharm Therapeutics Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Taiho Oncology, Inc. | 1 | $15 |
| Novocure Inc. | 1 | $15 |
| Syndax Pharmaceuticals, Inc. | 1 | $14 |
| Seagen Inc. | 1 | $13 |
How this compares
$912 in reported general payments places this provider in the 55th percentile of 418 radiation oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pilocarpine Hcl | 66 | $3,996 |
| Megestrol Acetate | 59 | $3,324 |
| Sucralfate | 76 | $2,388 |
| Tamsulosin Hcl | 125 | $1,720 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 70 | $1,660 |
| Triamcinolone Acetonide | 238 | $1,582 |
| Bicalutamide | 65 | $1,515 |
| SsdSilver Sulfadiazine | 49 | $743 |
| Dexamethasone | 32 | $716 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 17 | $433 |
| Silver Sulfadiazine | 22 | $352 |
| Ondansetron Hcl | 31 | $349 |
| Oxybutynin Chloride | 21 | $266 |
| Lidocaine Hcl ViscousLidocaine Hcl | 20 | $243 |
| Memantine Hcl | 13 | $175 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Paris
- Daniel GomezHouston$8.7M
- Neil DesaiDallas$8.6M
- Chad TangHouston$7.7M
- James WelshHouston$5.1M
- Caroline ChungHouston$3.7M
- Karen HoffmanHouston$2.6M
- Clifton FullerHouston$1.6M
- Robert TimmermanDallas$1.5M
- Steven LinHouston$1.5M
- Chenyang WangHouston$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.